A first preliminary confirmation comes from the work of Staufer et al. in which sAxl performed better in predicting advanced liver fibrosis (≥F2) when combined with serum albumin (in a sAxl/albumin ratio) in various chronic liver diseases [130]. This evidence concerns the gene ALB and Hepatic fibrosis.